Shows
ASRS's History of RetinaASRS Milestones in Retina: History of OCTIf there is one discovery that constituted a quantum leap in the evolution of the field of retina and ophthalmology, optical coherence tomography (OCT) is undoubtedly on the short list. Today’s retina specialists can’t imagine practicing without OCT imaging. It’s one of the first diagnostic tests obtained for the vast majority of patients, and is essential for the diagnosis and management of the most common retinal diseases, as well as the most rare. Join host Dr. Christina Weng as she traces this remarkable story of innovation with first-hand accounts from leading pioneers Drs. James G. Fujimoto, David...
2025-05-3037 min
Straight From The Cutter's Mouth: A Retina PodcastEpisode 456: From Chair to CEO with Dr. Jay DukerDr. Jay Duker joins the program to discuss his transition from chair of an ophthalmology department to President & CEO of Eyepoint Pharmaceuticals.Disclosures: Dr. Duker is President & CEO of Eyepoint Pharmaceuticals. Dr. Sridhar has consulted for Eyepoint Pharmaceuticals.You can claim CME credits for prior episodes via the AAO website. Visit https://www.aao.org/browse-multimedia?filter=Audi
2025-02-0400 min
New England Business Report with Kim Carrigan and Joe ShortsleeveBoston Buzz: Housing Hopes, Pharma Stays, Celtics Sale, and Coffee CrazeOn today’s program, Boston Business Journal reporter Greg Ryan talks about efforts to alleviate the housing shortage in Boston. The CEO of EyePoint Pharmaceuticals,Jay Duker, joins us to discuss his decision to stay in Massachusetts. Scott Kirsner, Innovation Reporter for The Boston Globe, talks about items that are still made in Massachusetts. Skip Perham, Suffolk University Professor of Sports business, explains the upcoming sale of the Boston Celtics. And finally, Rob Whitten, founder of Ping, explains how his new drive-through coffee machine works.
2024-11-0358 minASRS's History of RetinaASRS Milestones in Retina: History of Anti-VEGFJoin us for an extraordinary Milestones in Retina expert panel discussion detailing the discovery and evolution of a treatment that truly revolutionized the field of retina and the lives of patients around the world – virtually overnight. That therapy is, of course, anti-VEGF.It goes without saying that there is an army of researchers, clinicians, patients and industry representatives who contributed mightily to the success of this pivotal therapy. This new Milestones segment celebrates and shares the amazing story of innovation by tracking anti-VEGF’s miraculous discovery and the extraordinary therapeutic development that followed through the compelling first-hand acco...
2024-09-1949 min
HCPLive PodcastsNew Insight: Making Waves in the Biotech Space with Jay Duker, MDIn this episode, Veeral Sheth, MD, sits down with Jay Duker, MD, the president and chief operating officer of Eyepoint Pharmaceuticals, for a discussion on his storied career in ophthalmology, the importance of fostering a relationship between clinicians and industry, and the current biotech Dr. Duker and team are working on at Eyepoint.
Please direct any podcast-related inquiries to ciapoce@mjhlifesciences.com.
2023-05-2435 min
EyePodWet AMD and the treatment burden on patientsDavid Hutton from Ophthalmology Times and Jay Duker talk about wet AMD and the burdens of treatment on patients thanks to the consistent need for follow-ups and more.
2023-05-0215 min
The Retina Channel PodcastE67-DAVIO Trial- extended release EYP-1901 for wet AMD- Dr. Jay DukerDr. Jay Duker speaks about the results of the DAVIO trial which was a phase 1 trial investigating an intravitreal implant (EYP-1901) containg vorolanib (a VEGF and receptor blocker) in a bioerodible Durasert implant for the treatment of wet AMD.
2023-04-1035 min
BroadEye: An Ophthalmology PodcastFrom the operating room to the C-suite in pharma - Dr. Jay DukerDr. Duker is an accomplished ophthalmologist, that is now the Chief Operating Officer of EyePoint Pharma, a biotech company that develops sustained-release medications to treat serious ocular disorders. We talked about his career path and what motivated him to move from a clinical to an executive position. For the 21 years before he took the COO position at EyePoint, Dr. Duker was the Director of the New England Eye Center (NEEC) and Professor and Chair of the Department of Ophthalmology at Tufts Medical Center, Tufts University School of Medicine in Boston, Massachusetts. Dr. Duker received his medical degree from Jefferson...
2022-04-2134 min
Retina SynthesisA Tyrosine Kinase Inhibitor that Successfully Treats nAMDWe discuss the DAVIO trial of EYP-1901 with Dr. Jay S. Duker, Chief Operating Officer of Eyepoint Pharmaceuticals.
2022-03-0317 minRetina SynthesisFocus on Dr. Jay S. Duker and EyePoint PharmaceuticalsJoin us in a discussion with Jay S. Duker, MD Chief Strategic Scientific Officer of EyePoint Pharmaceuticals. Director of New England Eye Center, Professor and Chair of Ophthalmology at Tufts University School of Medicine with our moderator Dr. Carmen Puliafito.
2021-03-0419 min
OIS Podcast | Ophthalmology's leading PodcastOIS Industry Panel on Retina Start-upsThis week on the OIS podcast, host Firas Rahhal, MD, Partner at ExSight Ventures & Retina Vitreous Associates Medical Group facilitates an illuminating discussion on the topic of retina start-ups with a focus on providing tips to anyone interested in joining the retina space. Our guests include Andrew Stewart, AVP, US Commercial Retina of Allergan; Jay Duker, MD, Chief Strategic Scientific Officer, EyePoint Pharmaceuticals; Paul Hallen, VP & Global Head, Retina & Glaucoma, Alcon; and Ram Palanki, PharmD, SVP, Commercial Strategy & Operations, REGENXBIO.Listen in as this group shares advice on the topics of talent, asset quality, company st...
2020-12-1640 min
OIS Podcast | Ophthalmology's leading PodcastA Dynamic Career in RetinaOur podcast guest this week is Jay Duker, Professor and Chairman of Ophthalmology at Tufts Medical Center. Here, Dr. Duker shares his perspective on exciting clinical trials happening in the posterior space. He also offers words of advice for clinicians interested in running a practice while holding a senior position in industry. Have A Listen.
2020-09-2344 min
OIS Podcast | Ophthalmology's leading PodcastWhat Impact Will Gene Therapy Deals Have on Patients? Start-Ups? Jay Duker, MD, Can Speak for Both.We dip into the gene therapy pool one more time, talking with Jay Duker, MD about Luxturna’s impact on ophthalmology. We also discuss how the acquisitions of Spark and Nightstar are benefiting earlier-stage gene therapy start-ups, including his own Hemera Biosciences.
2019-03-2122 min